Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of DS-2243a in advanced solid tumors
NL-OMON60786Phase 1Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DS-2243 in Nonhematologic neoplasms, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Primary endpoint(s). Started Jun 2025; status: recruiting.
02
Drugs
DS-2243
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON60786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60786.